Press Release

PhRMA Statement on the Earthquake in Japan

PhRMA March 16, 2011

Washington, D.C. (March 16, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani today released the following statement:

“PhRMA and our member companies express our deepest sympathy for the people of Japan during this very difficult time, especially those who have lost loved ones. Our companies will provide support to the Japanese people as the nation recovers from the Tohoku Pacific off-shore earthquake, both in the immediate aftermath and through the long recovery period. We will do everything we can to help ensure a stable supply of the world’s best medicines to Japanese patients.

“As the toll from the earthquake and tsunami are still being assessed, PhRMA Japan is taking a leadership role in facilitating information-sharing among our member companies in Japan. The office is currently developing a report to share with the Japanese government with an initial assessment of the impact of the disaster on the Japanese supply system.

“Rx Response – a coalition assembled by PhRMA to help ensure the steady supply of medicines during U.S.-based disasters, is assisting in these efforts. Rx Response partners include the drug and biotechnology manufacturing and distribution industries, hospitals, community pharmacies and the American Red Cross. The U.S. government has already turned to Rx Response with a request for information about potential supply chain impacts, demonstrating the coalition's ongoing role as a trusted source of information.

“A number of PhRMA member companies have pledged significant funds to relief organizations that are supporting disaster relief in Japan, including the American Red Cross, Save the Children and Americares. When it is appropriate, our members will work with the Ministry of Health, Labor and Welfare in Japan to provide medicines that will be necessary for the health of the people in the affected area.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.4 billion in 2010 in discovering and developing new medicines. Industry-wide research and investment reached a record $67.4 billion in 2010.

PhRMA Internet Address:
For information on how innovative medicines save lives, visit:
For information on the Partnership for Prescription Assistance, visit:
For more information on public health emergencies, visit
For information on the danger of imported drugs, visit: